Key clinical point: When a second biologic is needed for juvenile idiopathic arthritis (JIA), the mechanism of action does not appear to matter in terms of drug effectiveness outcomes or drug survival.
Major finding: At 6 months, there were no significant differences seen in effectiveness outcomes such as the Juvenile Arthritis Disease Activity Score (JADAS)-71, American College of Rheumatology Pediatric 90% Response, Minimal Disease Activity index, or the Minimal Clinically Important Difference (MCID).
Study details: Real-world, observational analysis of data on 241 children and adolescents with polyarticular JIA starting a second biologic.
Disclosures: Versus Arthritis (formerly Arthritis Research UK) and The British Society for Rheumatology provided funding support. Mrs. Kearsley-Fleet had no financial conflicts of interest to disclose.
Kearsley-Fleet L et al. Ann Rheum Dis. 2019 Jun;78(Suppl 2):74-5. Abstract OP0016. doi: 10.1136/annrheumdis-2019-eular.415.